On December 21, 2022, InflaRx GmbH and Staidson (Beijing) BioPharmaceuticals Co., Ltd. entered into a third addendum to the Co-Development Agreement, dated as of December 28, 2015 (the “Co-Development Addendum”). Pursuant to the terms of the Co-Development Addendum, the Company will receive royalties of 10% on net sales of BDB-001 (as defined in the Co-Development Addendum) for COVID-19 in China. The Company has granted Staidson an exclusive license for use in China to certain of Company's clinical, manufacturing and regulatory documentation regarding vilobelimab in order to support and facilitate the regulatory filing for BDB-001 for the treatment of severely ill COVID-19 patients with the Chinese National Medical Products Administration.